Division of Transplantation, Department of Surgery, Medical University of Vienna, Austria.
Semin Immunol. 2011 Aug;23(4):293-303. doi: 10.1016/j.smim.2011.04.002. Epub 2011 May 26.
Secondary, so-called costimulatory, signals are critically required for the process of T cell activation. Since landmark studies defined that T cells receiving a T cell receptor signal without a costimulatory signal, are tolerized in vitro, the investigation of T cell costimulation has attracted intense interest. Early studies demonstrated that interrupting T cell costimulation allows attenuation of the alloresponse, which is particularly difficult to modulate due to the clone size of alloreactive T cells. The understanding of costimulation has since evolved substantially and now encompasses not only positive signals involved in T cell activation but also negative signals inhibiting T cell activation and promoting T cell tolerance. Costimulation blockade has been used effectively for the induction of tolerance in rodent models of transplantation, but turned out to be less potent in large animals and humans. In this overview we will discuss the evolution of the concept of T cell costimulation, the potential of 'classical' and newly identified costimulation pathways as therapeutic targets for organ transplantation as well as progress towards clinical application of the first costimulation blocking compound.
次要的,所谓的共刺激信号,对于 T 细胞激活过程至关重要。自从有了里程碑式的研究定义,即 T 细胞在没有共刺激信号的情况下接受 T 细胞受体信号,会在体外耐受,因此 T 细胞共刺激的研究引起了极大的兴趣。早期的研究表明,中断 T 细胞共刺激可以减弱同种异体反应,由于同种反应性 T 细胞的克隆大小,这种反应特别难以调节。此后,对共刺激的理解有了实质性的发展,现在不仅包括参与 T 细胞激活的正信号,还包括抑制 T 细胞激活和促进 T 细胞耐受的负信号。在移植的啮齿动物模型中,共刺激阻断已被有效地用于诱导耐受,但在大型动物和人类中效果较差。在这篇综述中,我们将讨论 T 细胞共刺激概念的演变,以及“经典”和新发现的共刺激途径作为器官移植治疗靶点的潜力,以及朝着临床应用第一种共刺激阻断化合物的进展。